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Abstract
Interval breast cancers (IBC) have been of great concern since breast mammogram screening programs were
introduced. We compared IBC to screen-detected cancers (SDC). IBC accounted for one-ﬁfth of all breast
cancers diagnosed in women who followed the regional screening program. IBC appeared to be more
aggressive than SDC in terms of tumor invasiveness, size, and St Gallen molecular subtype, leading to worse
overall and disease-free survival.
Background: The introduction of breast screening programs has raised the problem of interval breast cancers (IBC).
The aims of this study were to analyze the impact of IBC on the screening program, to compare IBC and screen-
detected cancers (SDC), and to identify possible predictors of mortality. Patients and Methods: Patients with
breast cancer diagnosed during the regional breast screening program between January 2008 and December 2013 at
a single center in Italy were included. Demographic, preoperative, and postoperative data were prospectively collected
and retrospectively analyzed. Results: Five hundred thirty-four patients were enrolled; 106 women (19.9%) had IBC
and 428 women (80.1%) SDC. IBC presented more aggressive features compared to SDC, such as tumor invasive-
ness (95% vs. 85%; P ¼ .005), tumor size (� pT2 37% vs. 21%; P ¼ .001), grade (G3 39% vs. 17%; P < .001), and St
Gallen molecular subtype (triple negative 22% vs. 7%; P < .001), resulting in higher distant recurrence rate (8% vs.
2%; P ¼ .009) and worse overall and disease-free survival (P ¼ .03 and P ¼ .001, respectively). Cox multivariate
regression analysis identiﬁed St Gallen molecular subtype as the only predictor of mortality in patients with breast
cancer (P ¼ .03). Conclusion: IBC accounted for one-ﬁfth of all breast cancers diagnosed in women who followed the
regional screening program. Furthermore, IBC appeared to have more aggressive features compared to SDC, leading
to worse survival. These worse survivals depended on St Gallen molecular subtype.
Introduction
The American Cancer Society estimated that in 2016, breast
cancer would be the ﬁrst tumor discovered in new cancer cases
occurring in women in the United States, causing more than 40,000
deaths and remaining the second leading cause of cancer-related
death among women.1 The introduction of mammogram
screening allowed breast cancers to be detected at earlier stages,2
thus improving patients’ prognosis3 thanks to a breast cancere
related mortality reduction of 26%.4 Moreover, the screening
program led to more favorable tumor characteristics in terms of
tumor size, lymph node (LN) involvement, and hormone status.5
Besides this prognostic improvement, the screening program
raised 2 main problems: overdiagnosis of ductal carcinoma-in-situ
and interval breast cancers (IBC).6-9 IBC are deﬁned as in-situ or
invasive breast cancers diagnosed after a negative mammographic
screening examination and before the next recommended routine
screening mammogram.10-12 The literature has demonstrated that
IBC are more aggressive than screen-detected cancers (SDC) in terms
of tumor size, LN involvement, grade, and molecular features.10,13-18
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2The aims of this study were to analyze the impact of IBC on the
screening program, to compare IBC and SDC in terms of clinical
and pathologic characteristics, and to identify possible predictors of
mortality in patients with breast cancer diagnosed during the
screening program period.
Methods
This retrospective single-center cohort analysis was conducted on
prospectively recorded data extracted from the database of the Breast
Unit of Trieste, Italy. The database collected all patients with both
benign and malignant breast pathologies since 2004. Data on
patients’ follow-up and causes of death were retrieved from the
Computerized Medical Records of the Azienda Sanitaria
Universitaria Integrata di Trieste.
Inclusion and Exclusion Criteria
This study included women diagnosed with either ductal
carcinoma-in-situ and invasive cancer who followed the regional
mammographic screening program in Trieste, involving women
aged 50 to 69 years assessed biennially between January 2008 and
December 2013.
Since the regional mammographic screening program started in
January 2006, patients diagnosed with cancer in the ﬁrst biennium
(ie, 2006 to 2007, the ﬁrst prevalence round) were not included in
this study to reduce the bias due to the more aggressive breast
cancers diagnosed at the beginning of the screening program.
Patients following the screening program between 2014 and 2015
were not included in this study in order to not negatively inﬂuence
the ratio between IBC and SDC, because IBC could be diagnosed
until December 2017. Women who underwent screening
mammograms after January 2016 were not included because the
round is not yet completed.
Patients who had not undergone a screening mammogram within
the previous 2 years and those who had a history of breast cancer
were excluded.
Women included in this study were divided in 2 groups
according to the timing of tumor diagnosis: patients with cancers
diagnosed during a screening mammogram were classiﬁed as SDC,
and those who had cancers diagnosed within the 2 years after a
negative screening mammogram were identiﬁed as IBC.
Parameters Evaluated
The 2 groups were compared in terms of age, family history of
breast cancer, breast density at mammogram, tumor type and his-
tology, surgical procedure performed, pT, pN, stage, grade, Ki-67,
molecular subtype according to St Gallen criteria, adjuvant therapy,
radiotherapy, and survival.
Overall survival (OS) was calculated from the date of surgery
(or diagnostic biopsy for women without surgery) to the date of last
follow-up or death from any cause. Disease-free survival (DFS) was
calculated from the date of surgery (or diagnostic biopsy for women
without surgery) to the date of last follow-up or to the date of local
or distant metastasis. Deadline of follow-up for survival analysis was
set to October 2016.
The entire cohort was divided according to St Gallen molecular
subtype into luminal and nonluminal cancers, and OS was calcu-
lated for these 2 subcohorts.
Preoperative Evaluation
All patients underwent a mammogram and a breast ultrasound
(US). The Breast Imaging Reporting and Data System (BI-RADS)
of the American College of Radiology was used to refer to breast
composition categories and to assessment categories for mammo-
gram, US, and magnetic resonance imaging.19
US-guided ﬁne-needle aspiration cytology or stereotactic biopsy
was performed in all suspected breast lesions to obtain a deﬁnitive
diagnosis. If certain diagnosis was not reached or if the lesion was >
3 cm, a US-guided core needle biopsy with molecular subtype
evaluation was carried out. Patients with high-density breast tissue
(ie, BI-RADS C and D), breast microcalciﬁcations, lobular breast
cancers, and/or tumors > 4 cm underwent magnetic resonance
imaging. Patients with triple-negative cancers and/or tumors > 5 cm
proceeded to staging contrast-enhanced thoracoabdominal computed
tomography, bone scintigraphy, and positron emission tomography.
Axillary US was always performed before surgery to evaluate LN
status. If abnormal LNs were found, ﬁne-needle aspiration cytology
was carried out.
Women with a deﬁnitive diagnosis of breast cancer were invited
to undergo a clinical breast examination with a breast surgeon.
During the visit, a complete history of the patient was collected, and
a clinical examination of breasts and axillary LNs was performed.
All patients were offered pre- and postoperative psychological
support.
Surgical Procedure
All cases were evaluated and analyzed preoperatively during the
multidisciplinary meeting of the Breast Unit of Trieste, ofﬁcially
recognized by the European Society of Mastology in 2016.
Women with high-stage, triple-negative, or human epidermal
growth factor receptor 2 (HER-2)-positive breast cancers were
referred to neoadjuvant chemotherapy. The surgical procedure was
decided after evaluating the breast volumeetumor dimension ratio,
molecular subtype (when available), and patient preference. Patients
underwent breast conservation surgery (ie, quadrantectomy) or
mastectomy, mainly skin or nipple sparing. Immediate or delayed
breast reconstruction was usually carried out by plastic surgeons
after nonconservative breast surgery.
Patients with clinically negative LNs underwent sentinel LN
biopsy. Lymphoscintigraphy was performed the day before surgery
in all these patients, and the radioactive axillary sentinel LN was
localized by gamma probe. Sentinel LNs touch imprint cytologic
analysis was performed intraoperatively to detect axillary metastases.
Women with preoperative LNs involvement or positive sentinel LN
biopsy proceeded to axillary node dissection. All surgical procedures
were performed by 2 expert breast surgeons.
All patients signed informed consent preoperatively for the sur-
gical procedure and for data collection.
Postoperative Staging
Breast cancer stage was deﬁned according to the American Joint
Committee on Cancer.20 Tumor type was recorded according to the
World Health Organization classiﬁcation of breast tumors.21 The
histologic grade was assessed using the Nottingham system.22
Immunohistochemistry (IHC) was performed preoperatively in
case of ﬁne-needle aspiration biopsy and postoperatively in each
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3surgical specimen. Estrogen receptor (ER) and progesterone recep-
tor (PR) status, HER-2 status, and cell proliferation activity in terms
of Ki-67 were determined by IHC. According to the American
Society of Clinical Oncology, ER and PR status were considered
positive if at least 1% of cells were positive at IHC.23 HER-2 was
scored 3þ when there was a strong circumferential membranous
staining in more than 30% of invasive carcinoma cells, 2þ when a
moderate circumferential membranous staining in more than 10%
of invasive carcinoma cells was recorded, 1þ when a weak and
incomplete circumferential membranous staining was found in
more than 10% of invasive carcinoma cells, and 0 when no staining
was registered. A HER-2 score of 0 and 1þ was considered negative,
and a HER-2 score of 3þ was deﬁned positive. Tumors scored as
2þ were considered equivocal, and HER-2 status was then deter-
mined using ﬂuorescence in-situ hybridization.10,23 Ki-67 values
were measured as the percentage of positively stained malignant cells
among the total number of tumor cells assessed. A Ki-67 cutoff
point of 20% was deﬁned to separate low from high proliferation
grade.24 Tumors were classiﬁed according to the St Gallen 2013
guidelines. Molecular subtypes were reported as follows: luminal A
(ER and PR positive, Ki-67 < 20%, HER-2 negative), luminal
BeHER-2 negative (ER positive, PR positive or Ki-67 < 20%,
HER-2 negative), luminal BeHER-2 positive (ER and/or PR
positive, any Ki-67, HER-2 positive), HER-2 type (ER and PR
negatives, any Ki-67, HER-2 positive), or triple negative (ER, PR,
and HER-2 negative, any Ki-67).25
Adjuvant Therapy
Postoperative therapy was decided according to international
guidelines.25,26 Tumor stage, molecular subtype, and patient age
were the main parameters considered to decide which kind of
adjuvant therapy to provide.
Patients with positive hormone receptors were treated with
endocrine therapy (eg, tamoxifen, anastrazole), while patients with
Ki-67 > 20% and/or with triple-negative cancers received adjuvant
chemotherapy. Patients with HER-2epositive cancers were treated
with an association of chemotherapy and antieHER-2 monoclonal
antibodies (ie, trastuzumab).
Breast radiotherapy was provided to all patients who underwent
conservative breast surgery. Radiotherapy was provided post-
operatively with or without intraoperative radiotherapy as an
anticipated boost of radiation. Patients underwent chest radio-
therapy in cases of tumors > 5 cm, tumor inﬁltrating the chest wall,
positive internal mammary LNs, or > 4 positive axillary LNs at
lymphadenectomy.
All patients undertook a follow-up program at the Department of
Oncology with annual breast examination, mammogram, and breast
US for at least 5 years.
Statistical Analysis
Quantitative data are reported as mean, median, standard devi-
ation, and interquartile range [25th-75th percentile]. Qualitative
variables are expressed as absolute frequencies and percentages.
Differences in categorical data were compared by the chi-square test
or the Fisher exact test, as appropriate. Differences in continuous
variables (age at diagnosis) were compared by the Mann-Whitney
test. Univariate analyses of OS and DFS rates were performed by
the Kaplan-Meyer method. Differences between survival curves
were analyzed by the log-rank test (Mantel-Cox). Cox regression
analysis was performed to identify possible prognostic factors
(univariate and multivariate analysis with adjustment for con-
founders). Results are reported as hazard ratios and 95% conﬁdence
intervals. A level of 5% was set for statistical signiﬁcance. Statistical
analyses were carried by R 3.0.3 software (R Foundation for Sta-
tistical Computing, Vienna, Austria; http://www.r-project.org/).
Results
Comparison of Preoperative, Operative, and
Postoperative Parameters
Table 1 summarizes the parameters analyzed.
A total of 534 patients, 106 IBC (19.9%) and 428 SDC
(80.1%), were identiﬁed. Among the IBC group, 1 patient had a
bilateral breast cancer, whereas 12 patients had bilateral involvement
in the SDC group. The median age was 62 and 64 years for the IBC
and SDC groups, respectively (P ¼ .09).
Patients with at least one ﬁrst-degree relative with breast cancer
comprised 30% of the IBC group and 18% of the SDC group
(P ¼ .02).
The breast density, according to the BI-RADS classiﬁcation,
registered at the diagnostic mammogram showed that patients with
IBC had more high-density breasts than patients with SDC (BI-
RADS C and D, 45% and 25%, respectively; P < .001).
Twenty patients, 9 with IBC and 7 with SDC, were treated with
chemotherapy alone and did not undergo surgery.
The type of surgery performed statistically differed between the 2
groups, with 78% of IBC patients undergoing breast-conserving
surgery (ie, quadrantectomy) compared to 88% of SDC patients
(P ¼ .001). LN surgery in terms of axillary dissection was carried
out more often in the IBC group compared to the SDC group (31%
and 24%, respectively), but these data were not statistically signif-
icant (P ¼ .20).
Invasive cancers were the most common tumor type in both
groups, accounting for 95% of IBC and 85% of SDC (P ¼ .005).
Invasive ductal cancer was less commonly found in IBC compared
to SDC (66% vs. 74%; P ¼ .01), whereas invasive lobular cancers
were equally distributed between the 2 groups (23% vs. 22%,
respectively). One IBC patient had lymphoma, 2 SDC patients had
lymphoma, and 1 SDC patient had a phylloid tumor. These 4
patients were excluded from the analysis.
Of IBC, 37% were > 2 cm in size compared to SDC, of which
only 21% had dimensions > 2 cm (P ¼ .001).
Most patients in both groups did not have LN involvement. IBC
were node positive in 24% of patients compared to 17% of patients
with SDC; this difference was not statistically signiﬁcant.
Staging statistically differed between the 2 cohorts (P < .001),
with a prevalence of stage I tumors in the SDC group (69% vs.
55%; P ¼ .01) and stage IV cancers in the IBC group (9% vs. 1%;
P < .001). However, both groups had mainly stage I and II cancers.
IBC were poorly differentiated in 39% of patients, whereas SDC
were classiﬁed as G3 in 17% of cases (P < .001).
For molecular subtypes, according to St Gallen classiﬁcation,25
IBC had a more aggressive pattern than SDC. Of the IBC, 35%
were classiﬁed as luminal A, 25% as luminal BeHER-2 negative,
9% as luminal BeHER-2 positive, 9% as HER-2 positive, and 22%
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4as triple negative compared to SDC, which were 48% luminal A,
36% luminal BeHER-2 negative, 5% luminal BeHER-2 positive,
4% HER-2 positive, and 7% triple negative. The difference in this
distribution appeared to be statistically signiﬁcant (P < .001).
Patients with IBC were treated more often with adjuvant
chemotherapy, whereas patients with SDC usually received only
hormone therapy (P < .001). Breast radiotherapy was provided to
73% of IBC patients and 86% of SDC patients (P ¼ .002).










Mean (� SD) 63 � 11 63 � 6 .09
Median [25th-75th percentile] 62 [57-68] 64 [59-68]
Family History of Breast
Cancer
.02
None 59 (59%) 280 (70%)
First-degree relative 30 (30%) 72 (18%)
Second-degree relative 11 (11%) 48 (12%)
Unknown 6 28
BI-RADS
A-B 53 (55%) 320 (75%) <.001
C and D 44 (45%) 105 (25%)
Unknown 9 3
Breast Surgery .001
Conservative 76 (78%) 381 (88%)
Mastectomy 22 (22%) 52 (12%)
None 9 7
Lymph Node Surgerya .20
Only sentinel procedure 68 (69%) 325 (76%)
Axillary dissection 30 (31%) 104 (24%)
Unknown 3 0
Tumor Type .005
Invasive 101 (95%) 371 (85%)





Ductal 67 (66%) 279 (74%)
Lobular 23 (23%) 81 (22%)
Other (eg, medullary,
tubular, papillary)
12 (11%) 16 (4%)
Tumor Size (pT)c .001
pT1a-b 23 (23%) 142 (38%)
pT1c 41 (41%) 153 (41%)
pT2þ 37 (37%) 76 (21%)
Lymph Node Status (pN)a
N0 68 (69%) 325 (76%) .28
N1mi 6 (6%) 29 (7%)
Nþ 24 (25%) 75 (17%)
Unknown 3 0
Stagec
I 55 (55%) 249 (69%) <.001
II 26 (26%) 92 (25%) .01
III 10 (10%) 18 (5%) .89
IV 9 (9%) 2 (1%) .06
Unknown 1 10 <.001
Gradec
G1 9 (9%) 49 (14%) <.001









G3 39 (39%) 62 (17%)
Unknown 2 10
Proliferative Index Ki-67c
Ki-67 �20% 52 (53%) 122 (34%) <.001
Ki-67 <20% 46 (47%) 241 (66%)
Unknown 3 8
Molecular Subtypec
Luminal A 34 (35%) 173 (48%) <.001
Luminal BeHER-2 negative 24 (25%) 129 (36%)
Luminal BeHER-2 positive 9 (9%) 17 (5%)
HER-2 positive 9 (9%) 15 (4%)
Triple negative 21 (22%) 26 (7%)
Unknown 4 11
Adjuvant Therapy
Chemotherapy 58 (55%) 101 (24%) <.001
Only hormone therapy 42 (40%) 259 (62%)
None 6 (5%) 58 (14%)
Unknown 0 10
Radiotherapy
Yes 77 (73%) 360 (86%) .002
No 29 (27%) 60 (14%)
Unknown 0 8
Local Recurrence
Yes 3 (3%) 7 (2%) .42
No 103 (97%) 421 (98%)
Distant Recurrence
Yes 8 (8%) 9 (2%) .009
No 98 (92%) 419 (98%)
Follow-up
Disease-free 91 (86%) 394 (92%) .09
Alive with tumor 4 (4%) 6 (1%)
Dead 11 (10%) 28 (7%)
Cause of Death
Breast cancer 10 (91%) 14 (50%) .02
Other 1 (9%) 14 (50%)
Abbreviations: BI-RADS ¼ Breast Imaging Reporting and Data System; HER-2 ¼ human
epidermal growth factor receptor 2; IBC ¼ interval breast cancer; SDC ¼ screen-detected
cancer.
aLymph node surgery was performed in all invasive cancers and in ductal carcinoma-in-situ with
high-grade dysplasia.
bOne IBC patient and 5 SDC patients had 2 different histologic types of tumor.
cData evaluated for invasive breast cancers only.
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5The local recurrence rate was substantially the same in both
groups (3% in IBC and 2% in SDC; P ¼ .42), whereas the
development of distant metastases during the follow-up was more
frequent in the IBC group (8% vs. 2%; P ¼ .009).
Thirty-nine patients, 11 (10%) IBC and 28 (7%) SDC, died
during follow-up. Of the 11 patients belonging to the IBC group,
91% of deaths (10 patients) were due to breast cancer, compared to
50% (14 of 28 patients) of SDC patients (P ¼ .02).
Survival Analysis
Figures 1 and 2 show the Kaplan-Maier survival curves for OS
and DFS, respectively.
Every patient included in the OS analysis had a minimum of 36
days (1 patient died with metastatic breast cancer at diagnosis) to a
maximum of 8 years of follow-up. The mean follow-up period for
OS was 4.61 � 1.89 years, and the median [25th-75th percentile]
was 4.52 years [3.09-6.15]. The 5-year OS for IBC was 86%
Figure 1 Kaplan-Maier Survival Curve for Overall Survival
Abbreviations: IBC ¼ interval breast cancers; SDC ¼ screen-detected cancers.
Figure 2 Kaplan-Maier Survival Curve for Disease-Free Survival
Abbreviations: IBC ¼ interval breast cancers; SDC ¼ screen-detected cancers.
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6compared to 94% for SDC (P ¼ .03). After stratiﬁcation of the
cohort according to St Gallen molecular subtype, no statistically
signiﬁcant difference was found in 5-year OS for IBC and SDC in
both luminal and nonluminal cancers (89% vs. 95%, P ¼ .40 and
88% vs. 94%, P ¼ .32, respectively).
Every patient included in the DFS analysis had a minimum of 14
days (patient with metastatic breast cancer at diagnosis) to a
maximum of 8 years of follow-up. The mean follow-up period for
DFS was 4.55 � 1.92 years and the median [25th-75th percentile]
was 4.47 years [3.07-6.13]. The 5-year DFS for IBC was 85%
compared to 96% for SDC (P ¼ .001).
Univariate and Multivariate Analysis
The results of the univariate and multivariate Cox regression
analyses are reported in Tables 2 and 3, respectively.
Cox regression analysis was carried out to identify possible pre-
dictors of mortality in patients with breast cancer. In the Cox
univariate analysis, screening detection mode was a favorable
outcome (hazard ratio 0.46, 95% conﬁdence interval 0.23-0.93;
P ¼ .03), whereas large tumors, positive node status, G3 grade, high
Ki-67, and nonluminal tumors (mostly triple-negative breast can-
cers) were negative prognostic factors of mortality.
In multivariate analysis, after adjusting for other prognostic fac-
tors, only nonluminal molecular subtype was conﬁrmed as a nega-
tive prognostic factor for mortality (hazard ratio 2.45, 95%
conﬁdence interval 1.08-5.55; P ¼ .03).
Discussion
This study demonstrated and estimated the magnitude of the
problem of IBC on the breast screening program. Interval cancers
accounted for 19.9% of all breast malignancies diagnosed during the
regional screening program period in patients undergoing the screening
examinations. This result agrees with previously published data, which
report the incidence of IBC to be between 10% and 32.49%.27,28 The
fourth edition of the European guidelines for quality assurance in breast
cancer screening and diagnosis considered the IBC rate “desirable” as
inferior to 30% during the ﬁrst year after the negative screening
mammogram and less than 50% during the second year.29
The results obtained from this study suggested that SDC have
more favorable characteristics than IBC, which lead to better sur-
vival. Cancers diagnosed at the screening mammogram were less
invasive, smaller, and better differentiated, and they had less
aggressive molecular features. These characteristics explain the
higher rate of breast-conserving surgery in SDC patients and the
reduced administration of chemotherapy to these women.
Median age at diagnosis was lower in IBC patients compared to
SDC patients. Although not statistically signiﬁcant, this result is
supported by other studies, which suggested that IBC more often
involved younger women.17,30-32 This hypothesis could be rein-
forced by the fact that patients with IBC had higher-density breasts
(ie, BI-RADS C and D) at the diagnostic mammogram, a typical
feature of younger patients.33 A similar difference in breast density
distribution between SDC and IBC groups has been reported
elsewhere.18,30,33,34 Boyd et al35 stated that density found by
mammogram is strongly associated with the risk of breast cancer
detected by screening or between screening tests. Their results
showed how the odds ratio for the risk of breast cancer detected less
than 12 months after the last screening mammogram in patients
with a density of 75% or more was 17.8 compared to the odds ratio
of 3.5 for those detected during the screening program. Similar
results were found by Porter et al.36 A possible explanation for these





Interval breast cancers 1.00 (Reference)
Screen-detected cancers 0.46 (0.23-0.93) .03
Tumor Size
pT1 1.00 (Reference)
pT2þ 3.49 (1.85-6.60) <.001
Node Status
pNþ 1.00 (Reference)
pN0 0.343 (0.21-0.89) .02
Grade
G1/G2 1.00 (Reference)
G3 2.36 (1.14-4.86) .02
Ki-67 Status
<20% 1.00 (Reference)
�20% 2.78 (1.44-5.37) .002
St Gallen Molecular Subtype
Luminal A 1.00 (Reference)
Luminal BeHER-2 negative 2.50 (1.05-5.96) .04
Luminal BeHER-2 positive 3.87 (1.16-12.86) .02
HER-2 positive 2.49 (0.53-11.72) .24
Triple negative 5.20 (2.01-13.50) <.001
St Gallen Molecular Subtypea
Luminal 1.00 (Reference)
Nonluminal 2.60 (1.35-5.02) .004
Abbreviation: HER-2 ¼ human epidermal growth factor receptor 2.
aLuminal refers to luminal A and luminal BeHER-2-negative cancers; nonluminal refers to
luminal BeHER-2 positive, HER-2 type, and triple-negative cancers.





Interval breast cancers 1.00 (Reference)
Screen-detected cancers 0.96 (0.67-2.46) .92
Tumor Size
pT1 1.00 (Reference)
pT2þ 1.56 (0.67-3.59) .30
Node Status
pNþ 1.00 (Reference)
pN0 0.57 (0.25-1.26) .16
St Gallen Molecular Subtypea
Luminal 1.00 (Reference)
Nonluminal 2.20 (1.01-4.83) .03
aLuminal refers to luminal A and luminal BeHER-2-negative cancers; nonluminal refers to
luminal BeHER-2 positive, HER-2 type, and triple-negative cancers.
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7results is that high-density breasts, which are typically found in
younger women, could hide small cancers during the screening
mammogram, which become evident later at a higher stage.37 Ciatto
et al31 suggested as a possible solution to this problem shortening
the time interval between screening mammograms or routinely
using breast ultrasound to improve the sensitivity and efﬁcacy of the
screening program in patients with high-density breasts.
A family history of breast cancer is a well-known risk factor for
developing of breast cancer in general.8 Comparing SDC and IBC
in terms of family history have conﬂicting results in litera-
ture.8,16,33,36,38,39 Holm et al16 reported an effect of family history
on the risk of IBC, assuming a possible disparate genetic back-
ground of SDC and IBC. Our study conﬁrmed this effect, sug-
gesting women with a family history of breast cancer ought to be
placed on a diagnostic path for patients at high risk. Moran et al40
reported that lobular histology might be the cause of “missing”
cancers at mammograms, resulting in higher rates of falsely negative
mammograms. This result was used to justify the higher invasive
lobular cancer rates in IBC compared to SDC (21.1% vs. 11.1%;
P < .05).10 Although our study reported a statistically signiﬁcant
difference in histology distribution, invasive lobular cancer rates
were similar between IBC and SDC (23% vs. 22%, respectively).
IBC had features more likely to be aggressive, such as invasive-
ness, lesser differentiation, higher stage, and worse molecular char-
acteristics (ie, high Ki-67, HER-2 positive, and triple negative).
Most tumors diagnosed by mammograms are invasive cancers, and
they accounted for 95% of IBC and 85% of SDC. These results
appeared to be similar to the ones reported by Baré et al.17 In the
literature, IBC is described as being diagnosed at a higher stage
compared to SDC.10,36 This difference in staging may be the result
of the larger dimensions of IBC compared to SDC.10,17,18,24,36,41
This study showed that patients with LN involvement more often
belonged to the IBC group, even if this difference was not statis-
tically signiﬁcant. Most studies10,24,42 have found that patients with
IBC have a higher risk of having LN metastases; Porter et al36 re-
ported similar but not statistically signiﬁcant results (P ¼ .97).
The larger dimensions of IBC lesions explain the lower rate of
breast-conserving surgery and radiotherapy provided to these pa-
tients. Similarly, the comparable LN metastasis rate between the 2
groups justiﬁes the similar trend in LN surgery with a prevalence in
sentinel LN biopsy. In the literature, this difference in surgical
approach to treat the primary cancer was evident, as was the dif-
ference in nodal surgery. Pálka et al42 reported that 86.4% of SDC
patients underwent breast-conserving surgery compared to 54.2%
of IBC patients, and that axillary dissection was carried out in
53.1% of SDC and 79.2% of IBC patients (P< .001 in both cases).
IBC had higher Ki-67 and/or HER-2 expression and were more
often triple negative than SDC. The differences in molecular fea-
tures that we found are similar to the ones reported in litera-
ture.17,18,38 Studies have demonstrated that Ki-67 expression is
higher in IBC compared to SDC, and that Ki-67 of � 20% is
associated with an odds ratio of 2.11 to 4.18,38 Meshkat et al10
found that according to St Gallen molecular classiﬁcation, SDC
were mainly luminal A, whereas IBC accounted for more luminal B,
HER-2 type, and triple-negative cancers.
The different molecular patterns identiﬁed in the 2 groups
inﬂuenced the adjuvant therapeutic scheme patients had to follow.
Therefore, chemotherapy was administered more often to IBC pa-
tients, whereas hormone therapy alone was mainly provided to SDC
patients. These ﬁndings are in agreement with previously published
data.5,13,42
Falck et al24 compared mortality between symptomatic IBC and
SDC in luminal Aelike and noneluminal Aelike subgroups.
Their ﬁndings revealed that mortality was inﬂuenced by the type of
diagnosis (ie, IBC and SDC) in luminal Aelike cancers, but this
was not conﬁrmed for noneluminal Aelike cancers. In our study,
the OS after molecular stratiﬁcation did not show any statistically
signiﬁcant difference between SDC and IBC. We reported that
both 5-year OS and 5-year DFS were better for SDC compared to
IBC, and both these ﬁndings were statistically signiﬁcant. Rayson
et al13 reported similar results, demonstrating better OS and DFS
for SDC compared to “true” IBC (P ¼ .0017 and P ¼ .0016,
respectively).
In the present study, multivariate Cox regression analysis showed
that nonluminal molecular subtype was the only independent pre-
dictor of mortality. Although van der Vegt et al43 found that the
molecular pattern did not reach the statistical signiﬁcance in their
multivariate analysis, our results appear to be comparable to ﬁndings
reported by others.15,24,38 This result could be explained by the fact
that the poorer survival of patients with IBC is due to the higher
number of nonluminal cancers in this group and not to the timing
of the diagnosis per se.
Our study has several limitations. First, our study is retrospective,
but this was the only mode of study we could prepare; it appears
impossible to do otherwise. The second limitation is the incom-
pleteness of some data as a result of the impossibility of recovering
them all. Third, our cohort sample size, especially for IBC patients,
is rather small. A fourth limitation lies in the study’s duration of
follow-up, which is too short to perform a good evaluation of the
recurrence rate. Finally, we did not reevaluate the negative mam-
mograms of IBC patients to learn whether they were “true” IBC, as
other studies have done.8,37,44,45
The 2 main strengths of this study are the strict adherence to the
IBC deﬁnition and the enrollment period, including 3 complete
rounds of breast cancer screening and the following period during
which patients could develop IBC. This well-deﬁned enrollment
period allowed us to determine the exact incidence of IBC in our
population.
Larger studies are needed to conﬁrm our results.
Conclusion
This retrospective study found that IBC accounted for one-ﬁfth
of all breast cancers diagnosed in women who followed the regional
mammogram screening program in Trieste, Italy. These cancers
appeared to have more aggressive histologic and molecular features
compared to SDC, leading to worse survival. The poor survival
seemed to depend on the nonluminal molecular subtype, which was
more frequent in IBC.
Clinical Practice Points
� IBC are in-situ or invasive breast cancers diagnosed after a
negative mammogram screening examination and before the next
recommended routine screening mammogram.
� There is still no consensus about the aggressiveness of IBC.
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8 We analyzed 534 women who followed the regional breast
screening program between January 2008 and December 2013;
we found that 106 (19.9%) had IBC and 428 (80.1%) had
SDC.
 IBC appeared to be more aggressive compared to SDC in terms
of tumor invasiveness (95% vs. 85%), tumor size ( pT2 37%
vs. 21%), grade (G3 39% vs. 17%), and St Gallen molecular
subtype (triple negative 22% vs. 7%), resulting in a higher
distant recurrence rate (8% vs. 2%) and worse 5-year OS and
DFS (86% vs. 94% and 85% vs. 96%, respectively).
 Nonluminal molecular subtype were the only independent
prognostic factor.
 The impact of IBC on the screening program and the higher
aggressiveness of these tumors compared to SDC should lead to
the creation of more sensible imaging techniques and to a speciﬁc
diagnostic path for high-risk women.
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